• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Debate Rages On Over ‘Black Box’ Warning on Antidepressants

Debate Rages On Over ‘Black Box’ Warning on Antidepressants

November 1, 2014
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Short Description:

Debate Rages On Over ‘Black Box’ Warning on Antidepressants

Background:

It’s been 10 years since the US Food and Drug Administration (FDA) put a so-called ‘black box’ warning on certain antidepressants because of fears they can cause suicidal thoughts and behavior.

The psychiatric community continues to debate the value of that warning, and a pair of opposing viewpoints was recently featured in the New England Journal of Medicine. One called for removal of the warnings (http://bit.ly/1EC0cJb), while the other, written by a medical reviewer at the FDA and proponent of broader antidepressant labeling, challenged the safety claims of the anti-black box crowd (http://bit.ly/1olxGr1).

All antidepressants carry a warning label cautioning users that the medications may increase the risk of suicidal thoughts and behaviors in children and young adults. The FDA required the black box warnings in 2004 after data emerged linking the drug paroxetine (Paxil) to suicidal thoughts. Opponents argue the warnings overstate the real risk and discourage physicians from prescribing them to patients who could really benefit from antidepressants.

A recent report in Time magazine (http://ti.me/1oHlaCw) interviewed 17 leaders in the psychiatry field and asked their opinions: 11 said the FDA should remove the warnings; two said the media has overblown the risk, resulting in more panic than is necessary; and four support the warning labels. Among those four, three were involved in the FDA’s original decision to issue the black box warnings.

Despite the controversy, the FDA has no plans to reconsider the warnings, according to the Time article.

Related content:
Black Box Warning in Children and Adolescents

Child Psychiatry
KEYWORDS antidepressants news_of_note risk_management
www.thecarlatreport.com
Issue Date: November 1, 2014
SUBSCRIBE NOW
Table Of Contents
FDA Notice: Be Wary of Some Generic Versions of Concerta
Omega Fatty Acids Might Help Kids with Attention Deficits
Pediatrician Policy Statement: Schools Should Start Later for Healthier Teens
CDC Study: Kids Are Flocking to e-Cigarettes
Following Release from Prison, Suicide Risk Eighteen Times Higher
Debate Rages On Over ‘Black Box’ Warning on Antidepressants
Vyvanse: A Look at America’s Most Prescribed Stimulant
Intuniv: Exorbitant, Sedating, and Second-Line
A Balanced Approach to Treating ADHD
Pet Therapy for College Students
Danish Study Explains Most of Autism’s Rise
To Prevent Depression in Teens, Teach About Change
Daily Marijuana Use by Teens Creates Life Problems
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.